Comparison · NCT06729593-fb2ce013
Remdesivir + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 5
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Remdesivir + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 5. Trial comparisons, record NCT06729593-fb2ce013. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06729593-fb2ce013
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.568 | 0.422 | 0.703 | wilson | |
| Risk in group 2 | 0.581 | 0.433 | 0.716 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0132 | -0.212 | 0.187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.977 | 0.681 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 0.947 | 0.405 | 2.22 | log | |
| Number needed to treat, for one fewer participant with the outcome on Remdesivir + SOC than on Placebo + SOC | 75.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Remdesivir + SOC | Arm includes all participants who received Remdesivir and were randomized under strata 1 and 3 from the master protocol (NCT04843761).~Remdesivir: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.~Corticosteroid: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC. | 25 | 44 | OG000 |
| Group 2 | Placebo + SOC | Arm includes all participants who received Remdesivir Placebo and were randomized under strata 1 and 3 from the master protocol (NCT04843761).~Remdesivir Placebo: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.~Corticosteroid: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC. | 25 | 43 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Safety Outcome Through Day 5
- Description
- Composite safety outcome of a serious adverse event, Grade 3/4 adverse event, organ failure/serious infection, or death through Day 5
- Time frame
- Through Day 5
- Population
Source ClinicalTrials.gov
Trial
- Title
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
- NCT number
- NCT06729593
- Phases
- PHASE3
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Corticosteroid
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2025-10-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06729593?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06729593-fb2ce013